# EDGAR Filing Document

**Accession Number:** 0001590750
**File Stem:** 0001193125-26-092071
**Filing Date:** 2026-3
**Character Count:** 7602
**Document Hash:** 50d56915370b0c67efc65698eb3bb9c4
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-092071.hdr.sgml**: 20260304

**ACCESSION NUMBER**: 0001193125-26-092071

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260302

**FILED AS OF DATE**: 20260304

**DATE AS OF CHANGE**: 20260304

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Harmon Seth
- **CENTRAL INDEX KEY:** 0001993300

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36483
- **FILM NUMBER:** 26723522

**MAIL ADDRESS:**
- **STREET 1:** C/O VIRIDIAN THERAPEUTICS, INC.
- **STREET 2:** 221 CRESCENT STREET, SUITE 401
- **CITY:** WALTHAM
- **STATE:** MA
- **ZIP:** 02453
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Viridian Therapeutics, Inc.\DE
- **CENTRAL INDEX KEY:** 0001590750
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 471187261
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 221 CRESCENT STREET
- **STREET 2:** SUITE 103A
- **CITY:** WALTHAM
- **STATE:** MA
- **ZIP:** 02453
- **BUSINESS PHONE:** 617.272.4600

**MAIL ADDRESS:**
- **STREET 1:** 221 CRESCENT STREET
- **STREET 2:** SUITE 103A
- **CITY:** WALTHAM
- **STATE:** MA
- **ZIP:** 02453

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** MIRAGEN THERAPEUTICS, INC.
- **DATE OF NAME CHANGE:** 20170213

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** MIRAGEN THERAPEUTICS, INC.
- **DATE OF NAME CHANGE:** 20170213

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** SIGNAL GENETICS, INC.
- **DATE OF NAME CHANGE:** 20140710

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Harmon Seth<br><sub>(Last) (First) (Middle)</sub><br>C/O VIRIDIAN THERAPEUTICS, INC.<br>221 CRESCENT STREET, SUITE 103A<br><sub>(Street)</sub><br>WALTHAM, MA 02453<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-03-02 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_Chief Financial Officer_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Viridian Therapeutics, Inc.\DE [ VRDN ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2026-03-03 |  | M |  | 6267 | A | <sup>(2)</sup> | 9881<sup>(5)</sup> | D |  |
| Common Stock | 2026-03-03 |  | F |  | 2091 | D | $29.32 | 7790<sup>(5)</sup> | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Stock Option (Right to Buy) | $30.25 | 2026-03-02 |  | A |  | 102850 |  | <sup>(1)</sup> | 2036-03-02 | Common Stock | 102850 | $0.00 | 102850 | D |  |
| Restricted Stock Units | <sup>(2)</sup> | 2026-03-02 |  | A |  | 20550 |  | <sup>(3)</sup> | <sup>(3)</sup> | Common Stock | 20550 | $0.00 | 20550 | D |  |
| Restricted Stock Units | <sup>(2)</sup> | 2026-03-03 |  | M |  |  | 6267 | <sup>(4)</sup> | <sup>(4)</sup> | Common Stock | 6267 | $0.00 | 18801 | D |  |

---

### Footnotes:

(1) The option vests and becomes exercisable in 48 equal monthly installments following the date of the grant, subject to the Reporting Person's continued service to Issuer through each vesting date.  The date of the grant is March 2, 2026.

(2) Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of the Issuer.

(3) The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 2, 2026, subject to the Reporting Person's continued service to Issuer through each vesting date.

(4) The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 3, 2025, subject to the Reporting Person's continued service to Issuer through each vesting date.

(5) Includes 903 shares acquired on March 17, 2025 under Viridian Therapeutics, Inc.'s 2016 Employee Stock Purchase Plan and 1,000 shares acquired on September 17, 2025 under Viridian Therapeutics, Inc.'s 2025 Employee Stock Purchase Plan in transactions that were exempt under Rule 16b-3(c).

**Signature:** Jennifer Tousignant, Attorney-in-fact  
**Date:** 2026-03-04

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**